Recce Pharmaceuticals Ltd (ASX:RCE)

Australia flag Australia · Delayed Price · Currency is AUD
0.3100
+0.0100 (3.33%)
Jul 4, 2025, 1:25 PM AEST
-36.73%
Market Cap 86.51M
Revenue (ttm) 9.59M
Net Income (ttm) -17.94M
Shares Out 288.37M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,048
Average Volume 185,315
Open 0.3050
Previous Close 0.3000
Day's Range 0.3050 - 0.3100
52-Week Range 0.2750 - 0.5700
Beta 0.54
RSI 47.76
Earnings Date Aug 29, 2025

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, its product pipeline comprises R327 Intravenous, which is in Phas... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol RCE
Full Company Profile

Financial Performance

In 2024, Recce Pharmaceuticals's revenue was 5.03 million, an increase of 15.19% compared to the previous year's 4.37 million. Losses were -17.66 million, 35.1% more than in 2023.

Financial Statements

News

Delhi Police foil terror designs on Independence Day with arrest of 'IS man'

On most wanted list of agencies, suspect was doing recce at different locations

11 months ago - The Times of India